DaVita (NYSE:DVA) Issues FY 2024 Earnings Guidance

DaVita (NYSE:DVA) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 9.250-10.050 for the period, compared to the consensus estimate of 9.790. The company issued revenue guidance of -. DaVita also updated its FY24 guidance to $9.25-$10.05 EPS.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on DVA shares. Truist Financial increased their target price on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Barclays upped their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday. TD Cowen raised their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Bank of America upped their price objective on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. Finally, UBS Group lifted their target price on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $161.80.

DaVita Price Performance

Shares of DVA stock traded up $2.53 during trading hours on Friday, hitting $142.34. The stock had a trading volume of 419,790 shares, compared to its average volume of 817,015. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.12. The stock has a market capitalization of $11.67 billion, a price-to-earnings ratio of 15.08, a PEG ratio of 0.82 and a beta of 0.87. DaVita has a one year low of $76.64 and a one year high of $168.50. The stock’s 50-day moving average price is $157.96 and its two-hundred day moving average price is $145.97.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the previous year, the firm earned $2.85 EPS. The business’s revenue was up 4.6% compared to the same quarter last year. Equities analysts forecast that DaVita will post 9.84 EPS for the current year.

Insider Transactions at DaVita

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now owns 837,835 shares in the company, valued at $138,284,666.75. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the sale, the chief financial officer now owns 111,481 shares of the company’s stock, valued at $17,286,243.86. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 173,482 shares of company stock worth $27,387,069. 2.00% of the stock is currently owned by insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.